肿瘤细胞治疗研究
英文原题：Targeting DLL3: Innovative Strategies for Tumor Treatment.
Delta样配体3（DLL3）是一种致癌蛋白，在多种肿瘤中异常表达，尤其是在小细胞肺癌中。
Delta-like 3（DLL3）是一种在多种肿瘤中异常表达的致癌蛋白，尤其是在小细胞肺癌中。靶向 DLL3 的治疗近年来取得了显著进展，在临床前和临床中展现出令人鼓舞的疗效。本综述旨在探讨靶向 DLL3 的肿瘤治疗相关机制、挑战及未来机遇。首先介绍 DLL3 的生物学特征及其在 Notch 信号通路中的作用，深入探讨 DLL3 在肿瘤发生和癌症进展中的作用。接下来，描述当前靶向 DLL3 的治疗方法，包括抗体药物偶联物、T 细胞衔接器、CAR-T 细胞和放射性药物治疗，重点阐述其在临床试验中的有效性和安全性。尽管前景广阔，但由于肿瘤异质性、耐药性的产生、潜在的不良反应以及患者分层方面的障碍，DLL3 作为治疗靶点的应用仍面临困难。因此，还讨论了联合治疗的潜力、创新药物递送系统的应用以及正在进行的临床试验进展。最后，总结 DLL3 靶向治疗的潜力，强调多学科研究对于指导这一新兴治疗策略的临床应用和优化的重要性。这些方法可能提供新的治疗选择，有望开启肿瘤治疗的新时代。
Delta-like 3 (DLL3) is an oncogenic protein aberrantly expressed in several tumors, particularly in small-cell lung cancer. DLL3-targeted therapies have recently made significant progress, demonstrating promising preclinical and clinical efficacy. This review aims to explore the mechanisms, challenges, and future opportunities associated with therapies targeting DLL3 for cancer treatment. The biological characteristics of DLL3 and its role in the Notch signaling pathway are introduced first, delving into the role of DLL3 in tumorigenesis and cancer progression. Next, current therapeutic approaches targeting DLL3 are described, including antibody-drug conjugates, T cell engagers, chimeric antigen receptor T cells, and radiopharmaceutical therapy, highlighting their effectiveness and safety in clinical trials. Despite the promising prospects, difficulties remain in the use of DLL3 as a therapeutic target due to tumor heterogeneity, the development of resistance, potential adverse effects, and barriers to patient stratification. Therefore, the potential of combination therapies, the use of innovative drug delivery systems, and ongoing clinical trial advancements are also discussed. Finally, the potential of DLL3-targeted therapies is summarized, highlighting the importance of multidisciplinary research to guide the clinical application and optimization of this emerging treatment strategy. These approaches might provide new therapeutic options, potentially starting a new era in cancer treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
